Articlenpj aging2026
Peripheral immunosenescence biomarkers and longitudinal cognitive decline: a large population-based study.
Article in npj aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral immunosenescence has been increasingly implicated in dementia pathogenesis. However, the contributions of specific lymphocyte subsets to cognitive outcomes remain poorly defined, and evidence from large-scale longitudinal studies is scarce. We leveraged data from the US Health and Retirement Study (n = 7444; mean age: 67.7 ± 9.7 years). Our primary analysis calculated three ratio metrics to quantify T-cell immunosenescence: the CD4:CD8 ratio, CD4 + EMRA: Naïve and CD8 + EMRA: Naïve ratios. Their longitudinal associations with 6-year cognitive decline were evaluated by linear mixed model adjusted for multiple covariates. We found that a higher CD8 + EMRA: Naïve ratio was significantly associated with accelerated cognitive decline (-0.050 point/year per SD; 95% CI: -0.066 to -0.033, P < 0.001). A nonlinear association was observed for the CD4:CD8 ratio (P for nonlinearity = 0.033), with only an intermediate level (the third quartile) associated with a slower cognitive decline. No significant association was found for the CD4 + EMRA: Naïve ratio. This study reveals a compartmentalized pattern in the associations of immunosenescent metrics with cognitive aging. The findings indicate a specific detrimental pathway characterized by an elevated CD8 + EMRA:Naïve ratio, whereas balanced CD4:CD8 homeostasis may play a beneficial role.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.